Key Points
Question What are the costs and cost-effectiveness of chronic urticaria (CU) management strategies?
Findings In this systematic review including 17 unique studies, based on 2023 US dollars, median annual cost estimations for CU ranged from $5621 to $6933. Biologic omalizumab, 300 mg, for H1 antihistamine–refractory chronic spontaneous urticaria (CSU) appears to be cost-effective from a third-party payer’s perspective.
Meaning In this review, biologic omalizumab, 300 mg, for H1 antihistamine–refractory CSU offered good value for money in US health care services; price negotiations and rebates of high-cost drugs may help promote sustainability and more effective health care allocation for CU.
Abstract
Importance Although treatment for chronic urticaria (CU) has improved over the past decades, evidence regarding costs and net benefits associated with these treatment strategies have yet to be comprehensively characterized and synthesized.










